Navigation Links
UK is first to administer new anti-clotting technology

Volunteers at the Jack and Linda Gill Heart Institute at the University of Kentucky were the first ever to receive a new anti-clotting therapy. The drug and its antidote are being developed for their effectiveness in preventing blood clots while at the same time providing physicians the ability to rapidly reverse the effects of the blood thinner to help safeguard patients against uncontrolled bleeding.

More than 12 million patients are prescribed so-called "blood thinners" each year to prevent the formation of clots, which can block blood vessels, causing heart attacks, strokes and other debilitating or life-threatening conditions. Blood thinners, or antithrombotics, pose a risk of bleeding, particularly during surgery. The ability to stop the anti-clotting effects quickly could help protect patients from uncontrolled bleeding.

The Gill Heart Institute is one of two sites participating in the Phase 1 trial and is the first site to use the anti-clotting drug and its antidote.

This clinical trial will examine the drug's safety and tolerability in healthy volunteers as well as the antidote's ability to quickly reverse its effects. Although other new antithrombotics are undergoing testing in the U.S., this drug is believed to be the first of its kind.

"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously," said Dr. Steven R. Steinhubl, the study's principal investigator at UK and director of cardiovascular education and clinical research at the Gill Heart Institute and a UK College of Medicine associate professor of cardiology. "It could have far-reaching implications."

"The research capacity of the cardiology division at UK has skyrocketed in the last year. Millions of dollars in research projects are under way, and we have attracted world-recognized leaders in drug discovery and development, such as Dr. Steinhubl. Leaders of technology and pharm aceutical companies have visited us in Lexington and are entrusting us to pioneer the next-generation of medicines and devices to improve healthcare," said Dr. David Moliterno, professor and vice chair of medicine, and chief, division of cardiovascular medicine, UK College of Medicine, and co-director of the UK Gill Heart Institute.

"Our goal is simple: we want to help patients with heart and vascular disorders by being at the forefront. Our research efforts are clearly bringing Kentuckians closer to the leading edge of the best medicine has to offer," Moliterno said.


'"/>

Source:University of Kentucky


Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Love at first smell
3. Worlds largest rainforest drying experiment completes first phase
4. PCRM develops worlds first cruelty-free insulin assay
5. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
6. World-first Living Donor Islet Cell Transplant A Success; Procedure Offers Promise For Diabetics
7. DuPonts first biologically derived polymer receives global recognition
8. Anti cancer virotherapy well tolerated in first human administration, research finds
9. Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development
10. The first impact factor for PLoS Biology ?13.9
11. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce ... determined to be appropriate as a screening test at dairies and farms for raw ... system, and the Charm EZ Lite system. These systems are a combination incubator and ...
(Date:6/20/2017)... ... 20, 2017 , ... HorizonScan is providing food and ingredient ... likely threat to their products at the annual IFT conference in Las Vegas, ... expo attracts over 20,000 attendees representing food science professionals from over 90 countries ...
(Date:6/20/2017)... ... 20, 2017 , ... Do More with OHAUS , With the launch of ... in the weighing industry, to extending its expertise across the entire laboratory to a ... and more, allowing for its customers to 'Do More' in the lab. ...
(Date:6/19/2017)... ... June 19, 2017 , ... EDETEK, Inc., ... today that it is launching two new additions of its award-winning cloud-based platform ... capabilities at the DIA 2017 Annual Meeting in Chicago, IL, June 19-22, 2017. ...
Breaking Biology Technology: